Literature DB >> 22845777

Development of a novel ovarian cancer molecular target therapy against cancer-related transcriptional factor, NAC1.

Kentaro Nakayama1, Naomi Nakayama, Kohji Miyazaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22845777     DOI： 10.1111/j.1447-0756.2012.01946.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN： 1341-8076            Impact factor:   1.730


× No keyword cloud information.
  3 in total

1.  Loss of beclin 1 expression in ovarian cancer: A potential biomarker for predicting unfavorable outcomes.

Authors:  Toshiko Minamoto; Kentaro Nakayama; Kohei Nakamura; Hiroshi Katagiri; Razia Sultana; Tomoka Ishibashi; Masako Ishikawa; Hitomi Yamashita; Kaori Sanuki; Kouji Iida; Satoru Nakayama; Yoshiro Otsuki; Noriyuki Ishikawa; Satoru Kyo
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

2.  miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6.

Authors:  Weiwei Shan; Jun Li; Yang Bai; Xin Lu
Journal:  Tumour Biol       Date:  2015-11-09

Review 3.  Mechanisms of ovarian cancer metastasis: biochemical pathways.

Authors:  Kentaro Nakayama; Naomi Nakayama; Hiroshi Katagiri; Kohji Miyazaki
Journal:  Int J Mol Sci       Date:  2012-09-18       Impact factor: 6.208
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.